## OXY: Occidental Petroleum Corporation - XLE: Energy

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 2.45 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($39.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Is Occidental Petroleum (OXY) Pricing Reflecting Its Large DCF Upside?**
- Source: Simply Wall Street | 20260105T110841 | Bullish | Relevance: 100%
- This article analyzes Occidental Petroleum's (OXY) valuation using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) approaches. The DCF model indicates that OXY is significantly undervalued, suggesting an intrinsic value of $105.31 per share compared to its current price of $42.38. However, the P/E ratio suggests the stock is overvalued relative to its industry and fair ratio, trading at 28.6x compared to a fair ratio of 16.6x.

**2. Occidental Petroleum stock rises premarket: OXY climbs after $9.7B OxyChem sale — what investors watch next**
- Source: ts2.tech | 20260105T102226 | Somewhat-Bullish | Relevance: 100%
- Occidental Petroleum (OXY) shares rose in premarket trading following the completion of its $9.7 billion sale of the OxyChem unit to Berkshire Hathaway. Investors are focusing on how the company will deploy this cash to address leverage and enhance shareholder returns, particularly as oil prices remain volatile. The sale aims to sharpen Occidental's focus on its core oil-and-gas operations, although analyst sentiment remains mixed and concerns about future oil price weakness and retained legacy liabilities persist.

**3. Occidental Completes Sale of OxyChem**
- Source: euro-petrole.com | 20260105T101026 | Bullish | Relevance: 100%
- Occidental has announced the completion of the sale of its chemical business, OxyChem, to Berkshire Hathaway for $9.7 billion in cash. This transaction aims to strengthen Occidental's balance sheet and allow the company to focus on its oil and gas portfolio. Occidental subsidiary Environmental Resource Holdings, LLC (ERH) will retain OxyChem's legacy tort claims and environmental liabilities.

**4. Occidental Petroleum stock rises after $9.7 billion OxyChem sale — what traders watch next**
- Source: ts2.tech | 20260104T092231 | Bullish | Relevance: 100%
- Occidental Petroleum's stock rose 3.1% after completing the $9.7 billion cash sale of its OxyChem business to Berkshire Hathaway, improving its balance sheet and allowing it to refocus on oil and gas. The transaction includes debt reduction and separates the chemical business's earnings volatility from core operations. Investors are now looking for updated targets on leverage and shareholder returns, while traders await signals from the upcoming OPEC+ meeting and Friday's monthly employment report.

**5. Occidental Petroleum stock ends up 3% after $9.7B OxyChem sale to Berkshire closes — what investors watch next**
- Source: ts2.tech | 20260103T172100 | Bullish | Relevance: 100%
- Occidental Petroleum's shares increased 3.1% after the company finalized the sale of its OxyChem unit to Berkshire Hathaway for $9.7 billion, coupled with a significant debt redemption. This deal provides a large cash infusion, reducing Occidental's leverage and focusing its strategy on oil and gas. Investors are now watching for the upcoming OPEC+ meeting and U.S. inventory data for signals on future oil prices and the company's post-OxyChem earnings profile.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | UBS | $43 | $45 | -4% |
| 2025-12-11 | B of A Securiti | $44 | $45 | -2% |
| 2025-12-08 | JP Morgan | $44 | $51 | -14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | UBS | main | Neutral |
| 2025-12-11 | B of A Securiti | main | Neutral |
| 2025-12-08 | JP Morgan | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.19M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 3 |

**Top Holders:**
- Berkshire Hathaway, : 26.9% (0.0%)
- Vanguard Group Inc: 9.1% (+0.8%)
- Dodge & Cox Inc.: 8.1% (-0.5%)
- Blackrock Inc.: 5.0% (+3.4%)
- State Street Corpora: 3.9% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.45 elevated, pricing in significant growth expectations. Balance sheet: $1.0B free cash flow. Revenue declining -18% YoY, concerning. Analyst sentiment negative (3 target cuts vs 0 raises). Institutional flow bullish (5 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.6B |
| Beta | 0.38 |
| 52W Range | $34.78 - $53.20 |
| Short Interest | 5.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.45 |
| Forward P/E | 26.9 |
| Current P/E | 18.3 |
| YoY Growth | -32.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.3% to 1.6% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 51. OFD pattern: -MLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.61% (CS: 61) | Neutral |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 0.956x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $41.25
- **Stop Loss:** $39.09 (5.2% risk)
- **Target:** $43.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 638
- **Position Value:** $26,317.50
- **Portfolio %:** 26.32%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-17 (Est: $0.38)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.50 | $0.64 | +26.8% |
| 2025Q2 | $0.31 | $0.39 | +24.8% |
| 2025Q1 | $0.76 | $0.87 | +14.0% |
| 2024Q4 | $0.67 | $0.80 | +19.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*